Uttam Patil - ABVC Biopharma Chief Officer
| ABVC Stock | USD 0.47 0.01 1.06% |
Executive
Uttam Patil is Chief Officer of ABVC Biopharma
| Age | 38 |
| Address | 44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538 |
| Phone | (510)-668-0881 |
| Web | https://www.abvcpharma.com |
ABVC Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.4455) % which means that it has lost $0.4455 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.2036) %, meaning that it created substantial loss on money invested by shareholders. ABVC Biopharma's management efficiency ratios could be used to measure how well ABVC Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of December 11, 2024, Return On Tangible Assets is expected to decline to -0.76. In addition to that, Return On Capital Employed is expected to decline to -1.01. At present, ABVC Biopharma's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.6 M, whereas Total Current Assets are forecasted to decline to about 1.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Adam Esq | Dianthus Therapeutics | 38 | |
| Christopher Devall | Dominari Holdings | 41 | |
| Christian Taucher | Valneva SE ADR | N/A | |
| Patrick Helfrich | Vericel Corp Ord | N/A | |
| David Wambeke | DiaMedica Therapeutics | 40 | |
| John Leonard | Vaccinex | 77 | |
| Keith Gligorich | Veracyte | N/A | |
| Phillip MD | Veracyte | 58 | |
| Eric Burns | Vericel Corp Ord | N/A | |
| Ernest Smith | Vaccinex | 52 | |
| George CPA | Dominari Holdings | 56 | |
| Penny Tom | Equillium | N/A | |
| Roland DeAngelis | Vericel Corp Ord | N/A | |
| Joshua Drumm | Valneva SE ADR | N/A | |
| Judson Taylor | Dianthus Therapeutics | N/A | |
| Mark Rowen | Denali Therapeutics | N/A | |
| Carole MD | Denali Therapeutics | 51 | |
| Patrick Fowler | Vericel Corp Ord | N/A | |
| Jason Keyes | Equillium | 53 | |
| Hanneke Schuitemaker | Valneva SE ADR | N/A | |
| Jill CPA | Vaccinex | 52 | |
Management Performance
| Return On Equity | -3.2 | ||||
| Return On Asset | -0.45 |
ABVC Biopharma Leadership Team
Elected by the shareholders, the ABVC Biopharma's board of directors comprises two types of representatives: ABVC Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ABVC. The board's role is to monitor ABVC Biopharma's management team and ensure that shareholders' interests are well served. ABVC Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ABVC Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| TsungShann Jiang, Member Officer | ||
| Leeds Chow, Chief Officer | ||
| Howard MD, Pres CEO | ||
| ChiHsin King, Chief Officer | ||
| Uttam Patil, Chief Officer | ||
| Eugene Jiang, Chairman Officer | ||
| TsungShann EMBA, Chief Director |
ABVC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ABVC Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.2 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (8.34) % | ||||
| Current Valuation | 8.25 M | ||||
| Shares Outstanding | 12.24 M | ||||
| Shares Owned By Insiders | 22.92 % | ||||
| Shares Owned By Institutions | 3.01 % | ||||
| Number Of Shares Shorted | 333.63 K | ||||
| Price To Book | 0.73 X | ||||
| Price To Sales | 42.61 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Revenue Per Share 0.017 | Quarterly Revenue Growth 18.175 | Return On Assets (0.45) | Return On Equity (3.20) |
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.